Euro-Med Laboratories Phil., Inc. Announces Unaudited Consolidated Earnings Results for the Year Ended September 30, 2018
November 12, 2018 at 07:54 pm EST
Share
Euro-Med Laboratories Phil., Inc. announced unaudited consolidated earnings results for the year ended September 30, 2018. For the period, the company reported net sales were PHP 882.94 million against PHP 972.8 million a year ago. Operating income was PHP 134.2 million against PHP 135.68 million a year ago. EBIT was PHP 108.55 million against PHP 116.68 million a year ago. Net income was PHP 75.98 million against PHP 81.68 million a year ago. Basic and diluted per share was PHP 0.02 against PHP 0.02 a year ago.
For the nine months, the company reported net sales were PHP 2,565.099 million against PHP 2,601.128 million a year ago. Operating income was PHP 321.01 million against PHP 313.69 million a year ago. EBIT was PHP 244.099 million against PHP 242.096 million a year ago. Net income was PHP 170.86 million against PHP 169.46 million a year ago. Basic and diluted per share was PHP 0.04 against PHP 0.04 a year ago.
Euro-Med Laboratories Phil., Inc. is a Philippines-based company, which is engaged in the manufacturing of pharmaceutical products, such as large and small-volume parenteral and other solutions, inhalation, irrigation, and dialysis. It also manufactures sterile water for injection, and other solutions, such as ophthalmic, inhalation, irrigation and dialysis. The Company's segments include manufacturing pharmaceutical products, providing health and other care services, and development and operation of quick service restaurants. Its subsidiaries include Hemotek Renal Center, Inc. (Hemotek), and CafeFrance Corp (CafeFrance). Hemotek provides renal and other healthcare services and is engaged as a dialysis center. CafeFrance is engaged in the development and operation of quick service restaurant (QSR). CafeFrance is engaged in operating restaurants, bakeries, food services, catering, food production and other related services incidental thereto.